Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Hendricks

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
The AAPS Journal|February 18, 2025
Addressing Clinical Challenges in Aberrant Pharmacokinetics of Biologic Therapeutic Drugs: Investigating Sample Processing Procedure in the ImmunoassaysYih-Wen Chen, Olinda Davenport, Nancy Yu, et al.
Bioanalysis|August 13, 2019
Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and bloodRobert Hendricks, Dana Baker, Jochen Brumm, et al.
Mabs|December 9, 2014
Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case studyKun Peng, Keyang Xu, Luna Liu, et al.
Annals of Clinical and Translational Neurology|March 1, 2022
Development of an age-adjusted model for blood neurofilament light chainChristopher Harp, Gian-Andrea Thanei, Xiaoming Jia, et al.
Bioanalysis|August 14, 2015
Strategies to compare clinical antitherapeutic antibody data when changing assay platforms: a case studyZhihua Julia Qiu, Yong Ying, Sock-Cheng Lewin-Koh, et al.
The AAPS Journal|September 20, 2022
Nonclinical Pharmacokinetics, Pharmacodynamics, and Translational Model of RO7297089, A Novel Anti-BCMA/CD16A Bispecific Tetravalent Antibody for the Treatment of Multiple MyelomaHao Cai, Satoko Kakiuchi-Kiyota, Robert Hendricks, et al.
Clinical Hematology International|January 19, 2023
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple MyelomaTorben Plesner, Simon J Harrison, Hang Quach, et al.
Ebiomedicine|June 24, 2023
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trialsAmit Bar-Or, Gian-Andrea Thanei, Christopher Harp, et al.
Journal of Clinical Pharmacology|December 18, 2023
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)Elena Garralda, Do Youn Oh, Antoine Italiano, et al.
Leukemia|January 10, 2022
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myelomaSatoko Kakiuchi-Kiyota, Thorsten Ross, Heidi Ackerly Wallweber, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
The AAPS Journal|February 18, 2025
Addressing Clinical Challenges in Aberrant Pharmacokinetics of Biologic Therapeutic Drugs: Investigating Sample Processing Procedure in the ImmunoassaysYih-Wen Chen, Olinda Davenport, Nancy Yu, et al.
Bioanalysis|August 13, 2019
Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and bloodRobert Hendricks, Dana Baker, Jochen Brumm, et al.
Mabs|December 9, 2014
Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case studyKun Peng, Keyang Xu, Luna Liu, et al.
Annals of Clinical and Translational Neurology|March 1, 2022
Development of an age-adjusted model for blood neurofilament light chainChristopher Harp, Gian-Andrea Thanei, Xiaoming Jia, et al.
Bioanalysis|August 14, 2015
Strategies to compare clinical antitherapeutic antibody data when changing assay platforms: a case studyZhihua Julia Qiu, Yong Ying, Sock-Cheng Lewin-Koh, et al.
The AAPS Journal|September 20, 2022
Nonclinical Pharmacokinetics, Pharmacodynamics, and Translational Model of RO7297089, A Novel Anti-BCMA/CD16A Bispecific Tetravalent Antibody for the Treatment of Multiple MyelomaHao Cai, Satoko Kakiuchi-Kiyota, Robert Hendricks, et al.
Clinical Hematology International|January 19, 2023
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple MyelomaTorben Plesner, Simon J Harrison, Hang Quach, et al.
Ebiomedicine|June 24, 2023
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trialsAmit Bar-Or, Gian-Andrea Thanei, Christopher Harp, et al.
Journal of Clinical Pharmacology|December 18, 2023
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)Elena Garralda, Do Youn Oh, Antoine Italiano, et al.
Leukemia|January 10, 2022
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myelomaSatoko Kakiuchi-Kiyota, Thorsten Ross, Heidi Ackerly Wallweber, et al.
Pageof 3